InflaRx IFRX 深 滬
已收盤 10-31 16:00:00 美东时间
1.46
+0.140
+10.61%
華盛通- 最 高1.46
- 今 開1.32
- 成交量 32.02万股
- 最 低 1.32
- 昨 收 1.32
- 總市值 9891.08万
- 52周最高 2.815
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 0.7113
- 委 比 -89.04%
- 總股本 6774.71万
- 歷史最高 53.10
- 量 比 0.29
- 振 幅 10.61%
- 歷史最低 0.7113
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their on...
10-28 07:50
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.
10-25 00:47
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
InflaRx N.V. announced its participation in Guggenheim Securities' 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, in Boston, MA. The company will host a fireside chat on November 11 at 2:30 PM ET and conduct one-on-one investor meetings on the same day. InflaRx is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, with vilobelimab as a key drug candidate.
10-21 11:20
InflaRx regains Nasdaq minimum bid price compliance
InflaRx (NASDAQ:IFRX) on Friday said it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement, per a notice from the exchange dated September 11. Company met the requirement after ...
09-12 20:51
InflaRx Regains Nasdaq Compliance
InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"),
09-12 20:36
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
<p>InflaRx N.V. announced that it has regained compliance with Nasdaq's minimum bid price requirement, as its ordinary shares closed at $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025. The company, which specializes in anti-inflammatory therapeutics targeting the complement system, developed vilobelimab, a novel anti-C5a monoclonal antibody, and is developing INF904, an orally administered C5a receptor inhibi...
09-12 12:30
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
HC Wainwright & Co. Assumes InflaRx at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $6.
09-02 18:49
InflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2025: the Cantor Global Healthcare Conference in New York on September 4th and the H.C. Wainwright Global Investment Conference on September 9th. They will present and hold one-on-one meetings. Links to the live streams and replays are available. rtc sean的SDKキー
08-21 11:30
InflaRx shares are trading lower after the company reported worse-than-expected Q2 financial results.
InflaRx shares are trading lower after the company reported worse-than-expected...
08-07 22:46
